🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07736885
Recruiting Not applicable

Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment

NCT07736885 · tracked via the Priya Life Science China tracker
Sponsor
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Phase
Not applicable
Started
2026-08-15
Last updated
2026-07-30

Condition(s) studied

Post-Stroke Cognitive Impairment (PSCI)Ischemic StrokeCognitive Dysfunction, Cognitive DisorderHemorrhagic Strokes

Investigational drug(s) / intervention(s)

Transcutaneous Electrical Stimulation at Jing-Well AcupointsTranscutaneous Sham Electrical Stimulation at Jing-Well Acupoints

Transcutaneous Electrical Stimulation at Jing-Well Acupoints: Device-based transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1). A custom-designed portable electrical stimulator (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm). Stimulation parameters: square wave, frequency 10 Hz, pulse width 320 μs, intensity individually titrated to sensory threshold (typically 0-1 mA), session duration 30 minutes. Treatment schedule: 6 sessions per week (Monday-Saturday) for 4 consecutive weeks, totaling 24 sessions. Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.

Transcutaneous Sham Electrical Stimulation at Jing-Well Acupoints: Device-based sham transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1). A custom-designed portable electrical stimulator with open-circuit design (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm). The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback. Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total). Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.

Study summary

This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.

Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.

Who can participate: Adults aged \[35-80\] who have had an ischemic stroke and now have mild to moderate cognitive impairment.

What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.

Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.

Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.

Eligibility

Sex
ALL
Min age
35 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 35-80 years; 2. Stroke duration within 2 weeks to 6 months post-onset; 3. Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score \< 26; 4. Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.); 5. No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study; 6. Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form. Exclusion Criteria: 1. Unstable vital signs or life-threatening comorbidities; 2. Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.); 3. History of epilepsy or epileptic seizures; 4. Pregnant or lactating women; 5. Concurrent use of other medications affecting cognitive function; 6. Allergy to the study intervention device or history of serious adverse reactions; 7. Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.); 8. Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin Tianjin Municipality Recruiting

More First Teaching Hospital of Tianjin University of Traditional Chinese Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07736885 on ClinicalTrials.gov ↗ ← All trials in China